Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem

Nat Rev Drug Discov. 2017 Oct;16(10):736. doi: 10.1038/nrd.2017.153. Epub 2017 Sep 22.

¹ Critical Path Institute, Tucson, Arizona, USA.
² Biogen, Cambridge, Massachusetts, USA.
³ Food and Drug Administration, Bethesda, Maryland, USA.
⁴ TEVA, Cambridge, Massachusetts, USA. Present address: Massachusetts General Hospital, Harvard, Boston, Massachusetts, USA.
⁵ IXICO, London, UK.
⁶ Loma Linda University, Loma Linda, California, USA.
⁷ Alzheimer's Drug Discovery Foundation, New York, New York, USA. Present address: American Epilepsy Association, Chicago, Illinois, USA.
⁸ Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut, USA. Present address: TEVA, Malvern, Pennsylvania, USA.
⁹ UsAgainstAlzheimer's, Washington, DC, USA.
¹⁰ Boston University, Boston, Massachusetts, USA.
¹¹ Pfizer, Boston, Massachusetts, USA.
¹² AbbVie, North Chicago, Illinois, USA.
¹³ CHDI Foundation, Princeton, New Jersey, USA.
¹⁴ Pfizer, Boston, Massachusetts, USA. Present address: Homology Medicines, Boston, Massachusetts, USA.
¹⁵ Eli Lilly &Company, Indianapolis, Indianapolis, USA.
¹⁶ Oregon Health &Science University, Portland, Oregon, USA.

No abstract available

Publication types